Drug Target Review2024-02-09T16:00:00
Scientists have discovered that increasing the levels of the CDKL2 enzyme could stop CDD symptoms developing or worsening.
Already a member? Sign in
By highlighting cutting-edge research and its practical applications, Drug Target Review enables readers to make decisions that accelerate innovation, translate discoveries into therapies, and create tangible benefits for patients worldwide.
By becoming a member you join a connected and collaborative community driving the industry forward. Member benefits include:
2026-08-20T08:43:00Z
Author Dr Daniel Tillett
2026-08-17T14:16:00Z
Contributor Dr Rab Prinjha, Drug Target Review
2025-06-11T14:00:00
Sponsored by Eurofins Discovery
2026-06-15T11:00:00
Sponsored by Miltenyi Biotec
2024-02-01T11:52:50
Sponsored by Leica Microsystems
2026-05-25T07:00:00
Contributor Professor Neville Sanjana
2023-01-05T14:41:33
Sponsored by Cell Signaling Technology
Site powered by Webvision Cloud